The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...

JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today ...

CEO Kristian Teär has purchased shares in the period 10 January to 14 January 2025, which as of 13 January 2025 exceeded the reporting limit of EUR 20,000. As of 14 January 2025, Kristian Teär has ...

After hours: 7:26:26 p.m. EST Loading Chart for XERS ...

After hours: January 14 at 4:42:21 p.m. EST ...